Table 1 Baseline characteristics of the patients treated with chemotherapy
Baseline characteristics | n=45 |
|---|---|
Gender, n (%) | |
Male | 31 (75.6) |
Female | 14 (24.4) |
Age, median years (min-max) | 61.7 (18.9-76.6) |
ECOG PS, n(%) | |
0-1 | 41 (91.1) |
2-3 | 04 (8.9) |
Child-Pugh classification, n (%) | |
A | 33 (73.3) |
B | 11 (24.4) |
C | 1 (2.2) |
BCLC stage, n(%) | |
B | 11 (24.4) |
C | 34 (75.6) |
Chronic Liver Disease Etiology, n(%) | |
HCV | 20 (44.4) |
HBV | 9 (20.4) |
Alcohol | 8 (18.2) |
NASH | 3 (6.9) |
Hemochromatosis | 2 (4.5) |
Auto-immune Hepatitis | 2 (4.6) |
Cryptogenic | 1 (2.3) |
Previous treatment, n (%)a | |
Resection | 7 (15.6) |
RFA | 2 (4.4) |
Transplantation | 3 (6.7) |
TACE | 18 (40) |
None | 16 (35.6) |
Extrahepatic spread, n(%) | 30 (66.7) |
Vascular invasion, n(%) | 13 (28.9) |
CCT regimen (%) | |
Doxorubicin | 25 (55.6) |
mFLOX/CapOx | 9 (20) |
5FU | 8 (17.8) |
GemOx | 2 (4.4) |
Capecitabine plus IFN | 1 (2.2) |
Ascites (%) | 4 (8.9%) |
Alpha fetoprotein, median ng/ml (IQI) | 15514.4 (6683.5-24345.5) |
Bilirubin median mg/dl (IQI) | 1.27 (0.94 – 1.6) |